Liposomes Containing Imatinib Mesylate and Dexketoprofen Trometamol: Development and Characterization
Özlem ÇOBAN*, Zelihagül DEĞİM*°

*Department of Pharmaceutical Technology, Gazi University Faculty of Pharmacy, Taç Street, 06330, Ankara,Turkey
°Corresponding Author :
Phone: +90 (312) 241 86 53
Fax: +90 (312) 212 79 58
e-mail: zdegim@gmail.com

 

SUMMARY
Imatinib mesylate (IMA) is a tyrosine kinase receptor inhibitor and its anticancer efficiency hold on inhibition of Bcr-Abl
pathway. Dexketoprofen trometamol (DEX) is a non-sterodial anti-inflammatory drug and demonstrated its anticancer efficiency on particularly animals with colorectal cancer in recent studies. Therefore it is aimed both decreasing the pain which is appeared during cancer therapy and reducing tumor size. IMA and DEX were co-loaded into DPPC/Cholesterol /DSPE-PEG2000 liposomes using different methods of production. The formulations were evaluated
in terms of zeta potential, particle size distribution, polydispersity index, encapsulation efficiency and in vitro release profile and the optimal formulations were determined. As a result of studies we have obtained liposomes, which have low particle size, high zeta potential with negative charge, and high entrapment efficiency for both of drugs.

Key Words: Liposome, imatinib mesylate, drug combination, cancer